MLH1 and neoplasm: His condition has been assessed as a stable disease since the sixth cycle of the combined regimen.<h4>Conclusion</h4>This case highlights the remarkable response of our patient's ACC with MSI-H tumor, MLH1 spice mutation, and high TMB to treatment with a novel combination of EP-M and sintilimab.